Physician profile
Ryan Hackett
NPI 1710140249
$1,869.93
in general payments reported to CMS, 2019-2025
28 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $640 · 2021: $296 · 2022: $56.49 · 2023: $182 · 2024: $173 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $340.73 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $315.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $167.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $142.38 | 2019-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $104.33 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $92.17 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $74.16 | 2019-2020 | |
| Allergan, INC. | $65.63 | 2019-2021 | |
| Lilly USA, LLC | $59.54 | 2019-2023 | Mounjaro |
| Abbvie INC. | $53.23 | 2021-2023 | |
| Medtronic, INC. | $47.73 | 2025 | Minimed 780g |
| Esperion Therapeutics, INC. | $43.14 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $35.36 | 2024-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $35.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.32 | 2020-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.35 | 2020-2024 | |
| Kyowa Kirin, INC. | $26.06 | 2021 | |
| Mylan Specialty L.P. | $24.99 | 2019-2023 | Yupelri |
| Glaxosmithkline, LLC. | $23.58 | 2019-2020 | |
| Dexcom, INC. | $22.23 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $20.91 | 2020 | |
| Corium, LLC | $18.93 | 2023 | Adlarity |
| Bayer Healthcare Pharmaceuticals INC. | $18.26 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2020 | |
| Daiichi Sankyo INC. | $16.41 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.56 | 2025 | Voquezna |
| Eisai INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.